31 terminated. 31 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 31 | Terminated 31 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 2 | Terminated 2 |
Follow Liver Cirrhosis: new trials by email Literature Review of Liver Cirrhosis trials Research Report on Liver Cirrhosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly Placebo, Avenciguat - Hypertension, Portal, Liver Cirrhosis | Phase 2 | Terminated | Boehringer Ingelheim | 22 | 2024-01-03 | 2025-06-12 |
| Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) - Liver Cirrhosis | Phase 2 | Terminated | AstraZeneca | 205 | 2022-10-31 | 2026-09-25 |
| Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy AXA1665, Placebo - Hepatic Encephalopathy | Phase 2 | Terminated | Axcella Health, Inc | 12 | 2021-06-29 | 2022-07-27 |
| Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy RBX7455, Placebo - Hepatic Encephalopathy, Cirrhosis, Liver | Phase 2 | Terminated | Ochsner Health System | 5 | 2021-03-01 | 2023-10-03 |
| Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis Align Probiotic Supplement Capsule, Placebos - Fatty Liver Disease, Fibrosis, Liver | Phase 1 / Phase 2 | Terminated | Corewell Health East | 14 | 2021-01-12 | 2022-09-27 |
| Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide. Ularitide, Placebo - Cirrhosis, Liver, Ascites Hepatic | Phase 2 | Terminated | University of Aarhus | 17 | 2020-08-01 | 2023-05-18 |
| Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC Obeticholic acid, Bezafibrate 200 MG, OCA Placebo - Primary Biliary Cholangitis | Phase 2 | Terminated | Intercept Pharmaceuticals | 75 | 2019-10-02 | 2026-07-16 |
| Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis CC-90001, Placebo - Non-alcoholic Fatty Liver Disease, Liver Cirrhosis | Phase 2 | Terminated | Celgene | 56 | 2019-08-14 | 2023-06-07 |
| Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus CR845 1.0 mg, Placebo - Cholestatic Pruritus | Phase 2 | Terminated | Cara Therapeutics, Inc. | 14 | 2019-06-25 | 2023-07-03 |
| A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA Baricitinib, Placebo - Primary Biliary Cholangitis | Phase 2 | Terminated | Eli Lilly and Company | 2 | 2019-03-28 | 2020-10-14 |
| Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis BCD-085 - Liver Cirrhosis, Biliary | Phase 2 | Terminated | Biocad | 9 | 2018-04-27 | 2019-10-11 |
| Low-Dose Danazol for the Treatment of Telomere Related Diseases Danazol - Telomere Disease | Phase 2 | Terminated | National Heart, Lung, and Blood Institute (NHLBI) | 18 | 2018-02-08 | 2026-10-27 |
| Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis APD334 - Primary Biliary Cholangitis | Phase 2 | Terminated | Arena Pharmaceuticals | 2 | 2017-12-29 | 2022-03-24 |
| Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid E6011, Placebo - Primary Biliary Cholangitis | Phase 2 | Terminated | EA Pharma Co., Ltd. | 29 | 2017-05-29 | 2019-01-04 |
| Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis Cenicriviroc - Nonalcoholic Steatohepatitis, Liver Cirrhosis | Phase 2 | Terminated | Tobira Therapeutics, Inc. | 167 | 2017-02-14 | 2022-02-02 |
| Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis Proton-pump inhibitor, Propranolol+Proton-pump inhibitor - Liver Cirrhosis, Peptic Ulcer | Phase 2 / Phase 3 | Terminated | Taipei Veterans General Hospital, Taiwan | 10 | 2016-12-26 | 2020-06-23 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis Cilofexor, Placebo to match cilofexor - Primary Biliary Cholangitis | Phase 2 | Terminated | Gilead Sciences | 71 | 2016-12-01 | 2020-09-22 |
| Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC) Placebo Comparator, Experimental: Seladelpar 50 mg, Experimental: Seladelpar / MBX-8025 200 mg - Primary Biliary Cirrhosis (PBC) | Phase 2 | Terminated | Gilead Sciences | 41 | 2015-11-04 | 2025-02-25 |
| IBAT Inhibitor A4250 for Cholestatic Pruritus A4250 - Biliary Cirrhosis, Primary | Phase 2 | Terminated | Sahlgrenska University Hospital | 9 | 2015-01-01 | 2017-02-23 |
| Sorafenib PK in Patients With Advanced HCC and Child-Pugh B Sorafenib, Midazolam clearance test, CYP cocktail clearance test - BCLC Stage C HCC, CP-B Liver Cirrhosis | Phase 2 | Terminated | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 5 | 2014-05-01 | 2019-08-21 |
Showing 20 of 31. Sign in to see all of them.
Liver Cirrhosis, Biliary (12) · Fibrosis (7) · Non-alcoholic Fatty Liver Disease (5) · Carcinoma, Hepatocellular (2) · Hepatic Encephalopathy (2) · Hypertension, Portal (2) · Liver Diseases (2) · Liver Neoplasms (2) · Pruritus (2) · Anemia, Aplastic (1) · Ascites (1) · Brain Diseases (1) · End Stage Liver Disease (1) · Fatigue (1)
Digestive System Diseases (31) · Pathologic Processes (31) · Pathological Conditions, Signs and Symptoms (31) · Liver Diseases (29) · Fibrosis (24) · Bile Duct Diseases (12) · Biliary Tract Diseases (12) · Cholestasis (12) · Cholestasis, Intrahepatic (12) · Fatty Liver (4) · Hepatic Insufficiency (3) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Signs and Symptoms (3)
obeticholic acid (2) · simtuzumab (2) · (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1) · 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1) · Bezafibrate (1) · Bosentan (1) · CC-90001 (1) · Capsules (1) · Carbamazepine (1) · Danazol (1) · Probiotics (1) · Propranolol (1) · Proton Pump Inhibitors (1) · S-Adenosylmethionine (1) · Sorafenib (1)
Gilead Sciences (4) · Intercept Pharmaceuticals (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Arena Pharmaceuticals (1) · AstraZeneca (1) · Axcella Health, Inc (1) · Biocad (1) · Boehringer Ingelheim (1) · Cara Therapeutics, Inc. (1) · Celgene (1) · Conatus Pharmaceuticals Inc. (1) · Corewell Health East (1) · EA Pharma Co., Ltd. (1) · Eli Lilly and Company (1) · Jules Bordet Institute (1)
United States (19) · United Kingdom (12) · France (9) · Germany (9) · Spain (9) · Canada (8) · Australia (5) · Austria (5) · Belgium (5) · Italy (5) · Poland (5) · Netherlands (4) · Puerto Rico (4) · Japan (3) · South Korea (3)
Alain Hendlisz, MD (1) · Andres Duarte-Rojo, M.D. (1) · Arena CT.gov Administrator (1) · Bhavisha Patel, M.D. (1) · David A Shapiro, MD (1) · David H. Perlmutter, M.D. (1) · Eduardo B Martins (1) · Eric Bellissant, MD, PhD (1) · Guilherme FM Rezende, MD, PhD (1) · Hanns-Ulrich Marschall, MD (1)
PMID 29990488, PMID 33307033, PMID 36750244, PMID 23664631, PMID 25500425, PMID 25543678, PMID 28818518, PMID 29486918
2016 (2), 2015 (1), 2018 (1), 2019 (1), 2023 (1), R21DK092567 (1)